Chang, H., Bartlett, S.E., Patterson, B., Chen, I.C. and Long, Y.Q. (2005) The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system. Bri- tish Journal of Haematology, 129, 539-541. doi:10.1111/j.1365-2141.2005.05493.x

has been cited by the following article:

• TITLE: New antimyeloma drugs in spinal cord infiltration for multiple myeloma. Determination of lenalidomide in cerebrospinal fluid with ultrasensitive high-performance liquid chromatography

  AUTHORS: Inmaculada Rapado, Juan José Lahuerta, Laura Montejano, María Ángeles Montalbán, Laura Pares, Joaquín Martínez- López

  KEYWORDS: Lenalidomide; Multiple Myeloma; Spinal Cord Infiltration; High-Performance Liquid Chromatography

  JOURNAL NAME: Modern Chemotherapy, Vol.1 No.2, October 15, 2012

  ABSTRACT: A 64-year-old woman with IgA kappa multiple myeloma was treated with thalidomide-dexa- methasone. Due to progression of the disease, bortezomib, doxorubicin and dexamethasone were administered, followed by autologous stem cell transplantation. Although near-complete remission was achieved, 5 months later, neuro- logical symptoms appeared and the patient was diagnosed with multiple myeloma with cells in- filtrating the spinal cord. Bis-chloronitrosourea, bortezomib and lenalidomide were then admin- istered and although the patient remained neu- rologically asymptomatic, she died 3 months later becausee of disease progression. Lena- lidomide entered into the cerebrospinal fluid (confirmed by ultrasensitive high-performance liquid chromatography), although did not im- prove the poor prognosis of multiple myeloma involving the central nervous system.